Erratum for

• Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study.

  Mitani K, Lee JW, Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Murotani K, Shimizu M, Matsuda A, Ozawa K, Nakao S. Mitani K, et al. Blood Adv. 2024 Mar 26;8(6):1415-1419. doi: 10.1182/bloodadvances.2023010959. Blood Adv. 2024. PMID: 38134300 Free PMC article. Clinical Trial. No abstract available.